India, Sept. 29 -- Cognition Therapeutics Inc. (CGTX), a clinical-stage biopharmaceutical company, on Tuesday reported the upcoming Type C meeting with the U.S. Food and Drug Administration (FDA) Division of Neurology regarding a planned Phase 3 registrational study of Zervimesine in treating dementia patients with Lewy bodies (DLB) experiencing psychotic symptoms.
Dementia with Lewy bodies (DLB) is a progressive and eventually fatal neurological disease, characterized by neuropsychiatric, cognitive, and motor dysfunctions. Up to 80% of those diagnosed may exhibit psychosis, marked by hallucinations and delusions, and these are often not treated wholly by antipsychotic medications.
Zervimesine (CT1812) is an investigational, once-daily or...